tiprankstipranks
Advertisement
Advertisement
Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)
PremiumThe FlyOruka Therapeutics reports Q2 EPS (55c), consensus (50c)
19d ago
Oruka Therapeutics: Buy Rating Reaffirmed as EVERLAST-A Data Support Once-Yearly ORKA-001; $120 Price Target Maintained
Premium
Ratings
Oruka Therapeutics: Buy Rating Reaffirmed as EVERLAST-A Data Support Once-Yearly ORKA-001; $120 Price Target Maintained
26d ago
Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
Premium
Ratings
Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
29d ago
Oruka Therapeutics Shareholders Back Governance and Executive Pay
PremiumCompany AnnouncementsOruka Therapeutics Shareholders Back Governance and Executive Pay
3M ago
Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged
Premium
Ratings
Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged
3M ago
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
Premium
Company Announcements
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100